GeneSight Moderate Interaction (Bins 1 and 7) Interpretation
A moderate gene-drug interaction on GeneSight indicates the medication may require dose adjustments or closer monitoring due to genetic variants affecting drug metabolism, and is associated with increased risk of side effects compared to medications in the low-interaction bin, though less concerning than high-interaction medications.
What the Bins Mean
GeneSight categorizes medications into three bins based on gene-drug interaction probability:
- Bin 1 (Green): "Use as directed" - minimal genetic interaction
- Bin 7 (Yellow): "Use with caution" - moderate genetic interaction
- Red bin: "Use with increased caution and more frequent monitoring" - high genetic interaction
The moderate interaction category (bin 7) falls between these extremes 1, 2.
Clinical Significance
Side Effect Risk: Patients taking medications from the moderate or high gene-drug interaction bins experience significantly more side effects than those on low-interaction medications. In adolescents with depression, those on high-interaction medications had notably higher side effect rates at 8 weeks (p=0.001) and 6 months (p<0.0001) 2.
Efficacy Considerations: The evidence shows that depressive symptom improvement does not differ significantly across medication bins 2. This means moderate interactions primarily affect tolerability and side effects rather than whether the medication will work.
Underlying Mechanisms
Moderate interactions typically involve:
- CYP450 enzyme variants (particularly CYP2D6 and CYP2C19) that alter drug metabolism 3, 4
- Medications dependent on oxidative metabolism for clearance are more likely to fall into yellow/red bins 1
- Drug-induced phenoconversion when multiple medications inhibit the same metabolic pathways 4
Clinical Action Steps
When a medication shows moderate interaction:
- Increased monitoring frequency: Check for side effects more closely than with green-bin medications
- Consider dose adjustments: May need lower starting doses or slower titration based on metabolizer status
- Watch for drug accumulation: Particularly if the patient is a poor metabolizer (PM) or taking CYP inhibitors concurrently 5, 3
- Evaluate alternatives: If side effects emerge, consider switching to a medication in the green bin rather than adding medications to manage side effects (avoiding prescribing cascades) 4
Important Caveats
Limited evidence base: Current pharmacogenetic testing guidelines, including from the American Academy of Pediatrics, state there is insufficient evidence to recommend routine use of these multi-gene panels for clinical decision-making 6. The genetic variants have not been fully studied regarding medication effects on symptoms, findings are inconsistent, and effect sizes may not ensure clinical utility 6.
Predictable from pharmacology: The bin placement can often be predicted based on whether drugs depend on oxidative metabolism - newer medications and those not dependent on CYP metabolism tend to be in green bins 1.
Population studied: Most evidence comes from depression studies, so generalizability to other conditions (anxiety, schizophrenia) is uncertain 7.
Cost considerations: These tests typically cost thousands of dollars and are often not covered by insurance 6.
Bottom Line Algorithm
- If medication is in moderate bin AND patient tolerates it well: Continue current therapy with routine monitoring
- If medication is in moderate bin AND patient has side effects: Switch to green-bin alternative rather than adding medications to manage side effects
- If starting new medication in moderate bin: Use lower starting dose, slower titration, and monitor more frequently for side effects in first 8 weeks 2
The moderate interaction designation serves primarily as a flag for heightened side effect vigilance rather than a contraindication to use 2, 7, 8.